Krish Ramadurai</a> is a Partner at <a href=https://medcitynews.com/author/kramadurai/"https://harmonixfund.com/">Harmonix Fund</a> where he leads the firm’s technical due diligence, investment sourcing, and portfolio operational support across their healthcare, life sciences, and deep technology practices. He is a multi-published author, advisor, lecturer, and former scientific researcher at Harvard and MIT. While at Harvard, he worked with Nobel Laureate Economist Michael Kremer on the United States Agency for International Development’s Innovation Ventures Fund and authored three books on medicine and applied engineering. Krish serves as a venture advisor for Nucleate (a global bioentrepreneur community) and is a board observer for Sorcero and xCures. Notably, he has received nominations for esteemed industry accolades, including Forbes 30 Under 30 in venture capital and the NVCA Rising Star Award. Krish has advanced degrees in biology, nanotechnology and nanomedicine, and business administration from Harvard University, Oxford University, and Washington University in St. Louis, respectively, and a bachelor’s degree in integrative biology and economics with a chemistry minor from the University of Illinois at Urbana-Champaign. In his spare time, he enjoys traveling and is an avid classic car enthusiast." /> Krish Ramadurai, Author at MedCity News

Krish Ramadurai

Krish Ramadurai is a Partner at Harmonix Fund where he leads the firm’s technical due diligence, investment sourcing, and portfolio operational support across their healthcare, life sciences, and deep technology practices. He is a multi-published author, advisor, lecturer, and former scientific researcher at Harvard and MIT. While at Harvard, he worked with Nobel Laureate Economist Michael Kremer on the United States Agency for International Development’s Innovation Ventures Fund and authored three books on medicine and applied engineering. Krish serves as a venture advisor for Nucleate (a global bioentrepreneur community) and is a board observer for Sorcero and xCures.

Notably, he has received nominations for esteemed industry accolades, including Forbes 30 Under 30 in venture capital and the NVCA Rising Star Award.

Krish has advanced degrees in biology, nanotechnology and nanomedicine, and business administration from Harvard University, Oxford University, and Washington University in St. Louis, respectively, and a bachelor’s degree in integrative biology and economics with a chemistry minor from the University of Illinois at Urbana-Champaign. In his spare time, he enjoys traveling and is an avid classic car enthusiast.

Posts by Krish Ramadurai

MedCity Influencers, BioPharma

The New Era of Programmable Biology

While legacy pharma companies battle in court with government agencies over how to address the costs that result from antiquated drug development paradigms, a growing cadre of compute-enabled life science companies are unlocking the nascent power of next-generation compute technologies to transform drug discovery and development.